Last reviewed · How we verify
DORZAGLIATIN
At a glance
| Generic name | DORZAGLIATIN |
|---|---|
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis (PHASE1)
- Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity (PHASE3)
- Glucokinase Activator in Monogenic Diabetes (PHASE2)
- Drug Interaction Study Between Dorzagliatin and Empagliflozin (PHASE1)
- Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes (NA)
- A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes (PHASE4)
- Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. (NA)
- Drug Interaction Study Between Dorzagliatin and Sitagliptin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |